An observational study in Angioplasty, Peripheral Arterial Disease and Iliac Artery Disease, sponsored by iVascular S.L.U.. Completed at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by iVascular S.L.U. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Peripheral Arterial Disease with a site in France — 21 open to participants now, 27 under way, 4 of them phase 3. Peripheral Arterial Disease · France.
Among the 120 studies in Peripheral Arterial Disease with a site in France, this one is the 31st largest by enrollment of the 54 observational ones that give a count, is one of 7 that started in 2022, is one of 54 observational ones, and was the 95th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →21 of the 120 studies in Peripheral Arterial Disease with a site in France are open now. Recruiting first, the newest first:
Poitiers University Hospital · Sites in France
Ages 18+
Intervascular · Sites in France, United States, Belgium and 1 more country
Ages 18+
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Sites in France
Ages 18+
Eli Lilly and Company · Sites in France, United States, Argentina and 15 more countries
Ages 18+
Atrium Medical Corporation · Sites in France, United States
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 13 · Phase 4 7
First in 2002; this study’s year is marked. 7 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 187 across 399 observational studies indexed under Peripheral Arterial Disease.
Median enrollment 106 across the 66 interventional studies, 298 across the 54 observational. Of the 82 that completed or were terminated, 12 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 120 have an industry lead sponsor. The 10 most frequent:
iVascular S.L.U. is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
iVascular S.L.U. has 3 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07283289Centre Hospitalier Intercommunal de Toulon La Seyne sur MerPrevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease | 2026-11 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
| NCT07322913IntervascularIntervascular Post-Market Clinical Follow-Up (PMCF) Registry | 2027-07 |
| NCT07181434Poitiers University HospitalImpact of Virtual Reality on Patient Pain During Lower Limb Revascularization Via Endovascular Surgery Under Local Anesthesia With Sedation | 2027-09-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 120 studies in Peripheral Arterial Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this prospective, multi-center, non-randomized, single-arm observational study is to evaluate the safety and the efficacy of the iCover covered stent over a 24-month follow-up period for the treatment of de novo iliac occlusive lesions, defined by a significant vessel stenosis ≥70%, in patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5).
This is a prospective, single-arm, multinational, and multicenter study conducted to evaluate the safety and efficacy of the iCover covered stent for the treatment of de novo iliac occlusive lesions (common and/or external iliac arteries) in patients with symptomatic lower limb arteriopathy. The primary endpoint of the study is primary patency, defined as the absence of restenosis in the target lesion over a 12-month follow-up period in patients who did not undergo a reintervention on the target lesion. Restenosis is defined as a reduction in the luminal diameter of more than 50%, assessed either by duplex ultrasound (considered as a peak systolic velocity index ≥ 2.4 at the target lesion) or by angio-CT (multiplanar reconstruction). Secondary endpoints include: technical and procedural success rate, freedom from all major adverse events, incidence of procedure- or device-related major local complications at the treated lesion, rate of SAEs, major amputation rate at the target limb, primary sustained clinical improvement (improvement in Rutherford classification), primary and secondary patency rates, TLR and TVR rates, and changes in ABI, the Walking Impairment Questionnaire, and the EQ-5D questionnaire from baseline.
Patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5). Patients with de novo atheromatous aorto-iliac lesions.
According to the incidence of TASC II lesions, approximately 70% of the patients will be classified as TASC II A or B lesions, while the other 30% will be classified as TASC II C or D lesions.
Inclusion criteria
Subjects will not be eligible to participate in the study if any of the following conditions are present in the subject:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Percutaneous transluminal angioplasty (PTA)
Device: Covered stent implantation
Percutaneous transluminal angioplasty (PTA) with iCover covered stent for the treatment of de novo aorto-iliac occlusive lesions
Primary Patency
The primary patency, defined as the absence of restenosis in the target lesion over the 12-month follow-up period in patients who did not undergo a reintervention on the target lesion.
Time frame: 12 months after index procedure.
Technical success rate
Technical success rate, defined as the ability to cross and dilate the lesion and achieve residual angiographic stenosis no greater than 30% after iCover stent graft insertion. Outcomes will be computed as the percentage of lesions treated at the end of the procedure.
Time frame: Day 0.
Procedural success rate
Procedural success rate, defined as technical success and no complications during the procedure including general and local complications as defined in the protocol. Outcomes will be computed as the percentage of patients at the end of the procedure.
Time frame: Day 0.
Freedom from All Major Adverse Event (MAEs)
MAEs are described as All-Cause Mortality post-procedure, Target Lesion Revascularization (TLR) post-procedure and Major Amputation of the Target Limb post-procedure (amputations above the ankle of the target leg).
Time frame: 1, 6, 12, 24 months after index procedure.
Incidence of Procedure- or Device- related Major Local Complications
Incidence of Procedure- or Device- related Major Local Complications at the treated lesion or Puncture Site up to 30 days post-procedure. Major Local Complications include: Iliac arterial rupture, retroperitoneal hematoma, thrombosis of the iliac axis on the ipsilateral side, need for surgery to achieve hemostasis, bleeding with loss of more than 2 g/ dL of hemoglobin, false aneurysm at the puncture site, preventing resumption of walking at 24 hours or appearance of ischemia on the ipsilateral side.
Time frame: Up to 30 days after index procedure.
Rates of Serious Adverse Events (SAEs)
Rates of SAEs, including both related and unrelated events. SAEs will be categorized as related or unrelated to the procedure/device based on adjudication by an Independent Clinical Events Committee.
Time frame: 1, 6, 12, 24 months after index procedure.
Major amputation at target limb rate
Percentage of patients with amputations above the ankle of the target leg will be counted.
Time frame: 1, 6, 12, 24 months after index procedure.
Primary sustained clinical improvement
Primary sustained clinical improvement defined as a sustained upward shift of 1 category of the Rutherford classification for patients with claudication, and by wound healing and rest pain resolution for patients in critical limb ischemia, without the need for repeated target lesion revascularization in surviving patients.
Time frame: 1, 6, 12, 24 months after index procedure.
Primary patency rates
Primary patency rates, defined as the lack of restenosis without reintervention of the target lesion. Restenosis is defined as a reduction in the luminal diameter of more than 50%, determined by either, duplex ultrasound examination considered as a peak systolic velocity index ≥ 2.4 at the target lesion, or by angio-CT (multiplanar reconstruction). In case of death, the vessel is considered as patent as long as no restenosis was detected during the last visit before the patient died. Outcomes will be computed as the percentage of lesions (Time frame: 6, 24 months after index procedure).
Time frame: 6 and 24 months after index procedure.
Secondary patency rates
Secondary patency rates, defined as the patency of the stent following an endovascular or surgical reintervention due to significant in-stent restenosis or occlusion. Outcomes computed as percentage of lesions.
Time frame: 6, 12, 24 months after index procedure.
Target lesion revascularization (TLR) rate
Target lesion revascularization (TLR) rate, defined as the need for repeated procedures (endovascular or surgical) due to a problem arising from the lesion initially treated in surviving patients with preserved limbs. Outcomes will be computed as the percentage of lesions.
Time frame: 1, 6, 12, 24 months after index procedure.
Target vessel revascularization (TVR) rate
Target vessel revascularization (TVR) rate, defined as the need for repeated procedures (endovascular or surgical) due to a problem arising remote from the vessel initially treated in surviving patients with preserved limbs. Outcomes will be computed as the percentage of lesions.
Time frame: 1, 6, 12, 24 months after index procedure.
Change in Ankle-Brachial Index (ABI) from baseline
Change in ABI from baseline.
Time frame: 1, 6, 12, 24 months post-procedure.
Change in Walking Impairment Questionnaire from baseline
The Walking Impairment Questionnaire values will be recorded and compared to the baseline values. This questionnaire is a validated tool to assess walking capability in patients with Peripheral Arterial Disease in different situations.
Time frame: 1, 6, 12, 24 months post-procedure.
Change in quality of life from baseline
Change in quality of life from baseline, as measured by EQ-5D. The EQ-5D Questionnaire values will be recorded and compared to the baseline values. It is a validated questionnaire to measure the quality of life based on 5 different parameters. Worst possible score in this study would be 0, best possible score would be 1. In addition, the patient indicates her/his current health on an analog scale from 0 (worst) to 100 (best).
Time frame: 1, 6, 12, 24 months post-procedure.
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2022 to primary completion in Jun 2025, 38 months.
Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 38 months is above that.
Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.
Completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Sep 2026, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.